Research and Development
Kansas State University, Manhattan, Kansas
The KBA awarded $300,000 to Kansas State University to create a county-level inventory of biomass resources such as agricultural crop residues; grain and oilseed crops; and herbaceous energy crops. As part of the KBA’s development of a strategic plan to advance the state’s national bioenergy leadership, this data will highlight opportunities for the state as its bioenergy sector expands to help the country meet the National Renewable Fuels Standard, which federally mandates a significant increase in non-corn based biofuel use (10/28/08).
Expected or Realized Outcomes: A comprehensive inventory of biomass resources in the state to support bioenergy industry growth.
ICM, Colwich, Kansas
The KBA awarded $1 million to Colwich-based ICM for a collaborative bioenergy research project to bring cellulosic ethanol solutions to the marketplace using non-food sources such as switchgrass, corn fiber, and sorghum. ICM will work with Edenspace Systems, Diamond Ag, and Kansas State University following the U.S. Department of Energy’s recent selection of ICM as one of four small-scale biorefinery companies to lead biomass-to-ethanol research efforts using innovative conversion technologies (10/28/08).
Expected or Realized Outcomes: $3 million in research funding.
University of Kansas Cancer Center, Kansas City, Kansas
The KBA awarded $750,000 to the University of Kansas Cancer Center to hire three researchers to support the work of center director Dr. Roy Jensen as KU seeks National Cancer Institute designation as a comprehensive cancer center (10/28/08).
Expected or Realized Outcomes: $300,000 per year in research funding.
Via Christi Medical Center, Wichita, Kansas
The KBA awarded $327,500 to Via Christi Medical Center to secure a researcher to work with KBA eminent scholar Dr. Paul Wooley as he studies the biocompatibility of composite implants leading to orthopedic surgery applications such as prosthetic joints (10/28/08).
Expected or Realized Outcomes: Approximately $750,000 in research funding.
Wichita Center for Graduate Medical Education, Wichita, Kansas
The KBA awarded $5.88 million to the Wichita Center for Graduate Medical Education for a research program that will lead to the creation of three new research centers. These centers are intended to improve health care delivery and patient outcomes; potentially lead to new drugs, medical products, and intellectual property; and serve as the basis for sustained accreditation of the 14 medical residency programs in Wichita (10/28/08).
Expected or Realized Outcomes: Three self-sustaining research centers.
Collaborative Cancer Research Initiative (CCRI), Kansas City, Kansas
The KBA will fund 10 to 15 awards totaling up to $2.5 million for cancer researchers across the country who partner with Kansas researchers on projects that leverage the state’s expertise and facilities. The initiative will enhance cancer research excellence in Kansas and nationally by introducing investigators to the state’s research facilities and strong expertise in drug discovery, delivery, and development. Academic, federal, and non-profit researchers will collaborate with Kansas scientists at the University of Kansas Cancer Center and elsewhere to perform cancer research not possible at their home institutions (6/5/08).
Expected or Realized Outcomes: Additional private and federal research spending.
Via Christi Health System and Wichita State University Eminent Scholar, Wichita, Kansas
The KBA awarded up to $911,954 over five years to attract eminent scholar Dr. Paul Wooley to Kansas to create an orthopedic immunogenetic laboratory to study the biocompatibility of composite implants, with the goal of developing alternatives to the metal joints used today in knee and hip replacements, which weaken bone mass and often require additional replacements over time. Dr. Wooley’s specialties include the pathology and treatment of connective tissue diseases, biocompatibility, tissue engineering, and gene therapy. He will serve as director of research at Via Christi’s Orthopaedic Research Institute and research professor at Wichita State University (4/8/08).
Expected or Realized Outcomes: Approximately $5 million in research funding over a five-year period and additional investment of $6.48 million.
Kansas Center for Biomaterials Innovation and Design, Wichita, Kansas
The KBA awarded a $200,000 planning grant for a proposed Kansas Center for Biomaterials Innovation and Design (KCBID) to establish a premier Kansas-based institution for biomaterials research and education and commercialization of the research into innovative medical devices. The lead applicants of this planning grant proposal are the University of Kansas and Wichita State University, in collaboration with Pittsburg State University’s Polymer Research Institute, the Research Centers of Via Christi Health System, and over 20 other private industries, educational institutions, and public organizations. The technology platforms in which KCBID will focus are development of biomaterials and medical devices for the dental and orthopedic (including spine) fields, with a secondary complementary focus on medical imaging, tissue engineering and combination products (1/16/08).
Expected or Realized Outcomes: A business plan to create a center of innovation for biomaterials.
Kansas Bioscience Innovation Center in Drug Delivery, Lawrence, Kansas
The KBA awarded a $180,000 planning grant for the proposed Kansas Bioscience Innovation Center in Drug Delivery (KBICDD) to transform outstanding drug-delivery capabilities at the University of Kansas into a completely integrated, high-performance, world-class drug-delivery organization. It is anticipated that the KBICDD will be a subsidiary of the Kansas University Center for Research, and KU plans to form the KBICDD based on a core concept of industry collaboration. The KBICDD also has secured the support and participation during the planning grant phase of virtually every drug discovery institution in the region, including both public and private research institutes; a wide range of biotechnology, biopharmaceutical, and drug specialty companies; contract research organizations; and animal health companies (1/16/08).
Expected or Realized Outcomes: A business plan to create a center of innovation for drug delivery.
Kansas Bioscience Innovation Center for Advanced Plant Design, Manhattan, Kansas
The KBA awarded a $200,000 planning grant for the Kansas Innovation Center for Advanced Plant Design. Proposed by the Kansas Wheat Commission, the center will focus on the emerging commercial opportunities for wheat, sorghum, small grains, and native plants and grasses. It will accelerate scientific discoveries and innovation in plant bioscience such as commercialization of sustainable, drought-tolerant, high-yielding varieties; foods with reduced allergenicity; new food products that are rich in anti-oxidants and cancer-fighting components; plant-derived medicines; and high bio-mass plants optimized for cellulosic bio-fuel production. Facilities for the center will be headquartered at Kansas State University in Manhattan, collaborating with existing research programs at the University of Kansas in Lawrence (1/16/08).
Expected or Realized Outcomes: A business plan to create a center of innovation for plant sciences.
University of Kansas Eminent Scholar, Lawrence, Kansas
The KBA awarded $5 million over five years to attract Dr. Blake Peterson to a tenured position in the KU School of Pharmacy. He will teach at both the professional and graduate level in the department of medicinal chemistry; develop and maintain an active research program; train graduate, undergraduate and postdoctoral students; and develop research collaborations across different disciplines within KU. Dr. Peterson is important to KU’s cancer drug discovery program, which is the heart of KU’s strategy for gaining National Cancer Institute designation as a cancer center. KBA funds would be used to assist in providing lab space, along with assistance from the KU Cancer Center. Dr. Peterson also has a high interest in technology transfer and commercialization. He is the founder of Indigo Biosciences, a preclinical contract research organization servicing clients involved in pharmaceutical R&D, biotechnology, and related sectors. Dr. Peterson has filed for 12 patent disclosures and been awarded over $7.2 million in NCI funding (1/16/08).
Expected or Realized Outcomes: An estimated $22 million in research funding over 10 years.
Kansas State University Eminent Scholar, Manhattan, Kansas
The KBA awarded up to $2,055,000 over five years to establish Dr. Juergen Richt (DVM, PhD) as a Regents distinguished professor at Kansas State University. Dr. Richt will have a primary faculty appointment in the Department of Diagnostic Medicine/Pathobiology, an academic unit of the College of Veterinary Medicine. He is expected to be a campus and statewide asset, providing animal health research leadership with investigators in the College of Veterinary Medicine, the university and the state. Dr. Richt’s infectious disease work requires a combination of BSL-3/BSL-3Ag biocontainment to be conducted in the Biosecurity Research Institute at K-State. He has been a lead scientist at the National Animal Disease Center (in the Virus and Prion Diseases of Livestock Research Unit) and a professor at Iowa State University. He is involved in cutting-edge research in two high-impact areas, prion diseases and influenza, and has established a strong reputation in the basic science of borna viruses and vaccines and diagnostics for other key viral diseases (1/16/08).
Expected or Realized Outcomes: Approximately $4 million in research funding over five years.
Collaborative Biosecurity Research Initiative, Manhattan, Kansas
The KBA has launched a $2.5 million Collaborative Biosecurity Research Initiative (CBRI) to bring together researchers nationwide to create products that protect Americans from the intentional use of animal-borne diseases to disrupt the national economy or to infect humans. The goal of the CBRI is to support inter-institutional research to: 1) develop counter-measures for foreign-animal diseases; 2) provide advanced test and evaluation capability for threat detection, vulnerability, and countermeasure assessment for animal and zoonotic diseases; 3) support licensure of vaccine countermeasures through essential animal-model testing and evaluation; and 4) strengthen biosecurity capabilities of institutions serving certain regions and populations (9/28/07).
Expected or Realized Outcomes: The CBRI will introduce the unique biosecurity research capabilities and facilities at Kansas State University to investigators nationally and develop strategic alliances to promptly confront animal- and public-health threats by leveraging multi-disciplinary expertise.
Commercialization
Pinnacle Technology, Lawrence, Kansas
The KBA awarded $375,000 to Pinnacle Technology for the commercialization of a wireless neurochemical biosensor for laboratory research that supports the pre-clinical development of new pharmaceuticals. The investment will partially match a Phase II Small Business Innovation Research grant from the National Institutes of Health (10/28/08).
Expected or Realized Outcomes: $840,000 in research funding.
NOWA Technology, Prairie Village, Kansas
The KBA awarded a $1.5 million loan to NOWA Technology to commercialize its patent-pending technology that chemically extracts marketable products such as fuel oil and mineral salts from municipal wastewater and eliminates the need to incinerate or landfill sludge. This proprietary process reduces wastewater treatment costs while providing significant environmental benefits (10/28/08).
Expected or Realized Outcomes: $2.5 million in private investment capital.
VasoGenix Pharmaceuticals, Lenexa, Kansas
The KBA awarded a $200,000 convertible note to support the development of an IV and controlled-release drug treatment for acute decompensated heart failure, a disease that affects 5 million people and 550,000 new patients annually. The company is completing pre-clinical studies of its treatment that uses a molecule with a history of safe use in humans and which aims to improve human health while reducing re-hospitalization costs by $6 billion per year (7/15/08).
Expected or Realized Outcomes: $200,000 in private investment.
KC BioMediX, Lenexa, Kansas
The KBA made an equity investment of $400,000 in KC BioMediX to commercialize technologies developed at the University of Kansas for the care of infants born prematurely. The company’s FDA-approved device, the NTrainer System, uses state-of-the-art hardware and software to treat preemies who have difficulty feeding orally so they can quickly gain strength and grow. This award follows a $150,000 KBA investment last fall and is part of a $4 million round of company financing (7/15/08).
Expected or Realized Outcomes: $3.6 million in private investment capital.
ImmunoGenetix Therapeutics, Lenexa, Kansas
The KBA awarded a $420,000 convertible note to ImmunoGenetix to support the development of its therapeutic vaccine for HIV designed to inhibit viral replication by enhancing antibody and cellular immune response. The company’s approach has the potential to reduce dependency on anti-HIV drug cocktails and diminish the emergence of drug-resistant HIV strains (6/5/08).
Expected or Realized Outcomes: $420,000 in private investment capital.
OsteoGeneX, Kansas City, Kansas
The KBA awarded $375,000 for the further development of a groundbreaking treatment to stop the advance of osteoporosis and related bone disorders. This grant, which is a partial match of a federal NIH/NIAMS Small Business Innovation Research grant, is OsteoGeneX’s second award from the KBA, following a $130,000 grant last year that resulted in the identification of several bone-building small molecules (6/5/08).
Expected or Realized Outcomes: $995,000 in federal research funding.
TVAX Biomedical, Lenexa, Kansas
The KBA awarded $187,622 to TVAX Biomedical for a clinical trial of a unique cancer treatment that uses a patient’s own immune cells to fight the disease (6/5/08).
Expected or Realized Outcomes: Progress in the FDA approval process.
Pinnacle Technology, Lawrence, Kansas
The KBA awarded up to $375,000 to Pinnacle Technologies, a Lawrence-based company that specializes in wireless, Web-enabled sensor conditioning, data acquisition, and biotechnology products, to develop real-time wireless monitoring and data acquisition systems for use in studying the brain activity of mice and rats. This technology will provide researchers with new tools to use in understanding the effects of degenerative brain disorders and developing cures for those disorders (1/16/08).
Expected or Realized Outcomes: Nine new employees and $879,290 in federal research funding.
Edenspace Systems Corporation, Junction City, Kansas
The KBA awarded $40,000 to support Edenspace’s breakthroughs in lowering processing costs and increasing yields of biofuels from sorghum, corn, and switchgrass. The KBA funding will serve as a 50 percent match to a Small Business Innovation Research grant the company has been awarded by the U.S. Department of Agriculture (11/26/07).
Expected or Realized Outcomes: $80,000 in federal research funding.
Edenspace Systems Corporation, Junction City, Kansas
The KBA awarded $50,000 to support Edenspace’s breakthroughs in lowering processing costs and increasing yields of biofuels from sorghum, corn, and switchgrass. The KBA funding will serve as a 50 percent match to a Small Business Innovation Research grant the company has been awarded by the U.S. Department of Energy (11/26/07).
CritiTech, Lawrence, Kansas
The KBA awarded $264,048 under the Bioscience Tax Investment Incentive Program to support CritiTech’s manufacture of fine-particle pharmaceuticals through a process known as precipitation with compressed antisolvent. The company is pursuing an investigational new drug application for its new product Nanotax (9/28/07).
Expected or Realized Outcomes: 25 to 30 new employees, $750,000 in private investment, and $400,000 in federal research funding.
Kansas Environmental Management Associates, Topeka, Kansas
The KBA awarded a $312,500 research and development voucher to Kansas Environmental Management Associates (KEMA) for a collaboration with the Advanced Manufacturing Institute to develop, construct, and operate a farm-scale phosphorous recovery system to remove up to 75 percent of the phosphorous from cattle feedlot lagoon water. KEMA has been leading an effort in conjunction with the AMI of Kansas State University to address the growing concern of excess nutrient level accumulation on farmland, specifically, phosphorous accumulation (9/28/07).
Expected or Realized Outcomes: 26 new employees and $65,000 in research funding.
OsteoGeneX, Kansas City, Kansas
The KBA awarded $130,000 to OsteoGeneX for the development of a small molecule inhibitor of the new bone anabolic target sclerostin (SOST) for the treatment of osteoporosis and related bone disorders. Through genomic approaches, sclerostin was identified as a master regulator of bone mass affecting men and women. Using proteomic approaches, OsteoGeneX discovered and patented sclerostin’s mechanism of action. Since then, the work was awarded a NIH Phase I SBIR proof-of-concept grant to screen a small molecule library for compounds blocking SOST function (7/10/07).
Expected or Realized Outcomes: Collaboration with the University of Kansas to identify the dosing of authenticated lead candidates and begin animal and clinical trials; approximately eight new employees; and $134,000 in federal research funding.
KC BioMediX, Shawnee, Kansas
The KBA awarded KC BioMediX a $150,000 convertible debenture to help commercialize technologies developed at the University of Kansas for the care and treatment of infants born prematurely, particularly assisting with the problem of non-nutritive sucking. KC BioMediX has licensed the sole rights to commercialize the technologies and devices described in two patent applications (7/10/07).
Expected or Realized Outcomes: Approximately 99 new employees $607,000 in capital expenditures, and $1.45 million in investment capital.
Innovia Medical, Lenexa, Kansas
The KBA awarded $300,000 equity investment to Innovia, plus up to an additional $350,000 if matched by Kansas private equity investors, to commercialize an FDA-approved product called EarCheck, which utilizes the only technology for the rapid detection of middle ear fluid, a key indication of ear infections (7/10/07).
Expected or Realized Outcomes: Three new employees in addition to $100,000 in capital expenditures and $3.1 million in investment capital.
Sunflower Integrated Bioenergy Center, Holcomb, Kansas
The KBA awarded $500,000 to the National Institute for Strategic Technology Acquisition and Commercialization (NISTAC) for a Phase II project to identify and commercialize renewable energy technology for western Kansas, including funding for engineering and economic/legal due diligence. Sunflower Electric Power Corporation will contribute the land, and NISTAC will contribute intellectual property (1/9/07 and 3/13/07 for Phase II after recommendation).
Expected or Realized Outcomes: Approximately 161 new employees, $278,000 in research funding, and $400 million in capital expenditures.
CritiTech, Lawrence, Kansas
The KBA awarded $48,700 to CritiTech to create smaller and more uniform particles in the area of drug delivery. Funding is for the purchase and setup of a new and improved coating unit, greatly expanding CritiTech’s capacity to perform feasibility and development projects for pharmaceutical companies (7/13/06).
Expected or Realized Outcomes: Two new employees and $100,000 in federal research funds.
Nutri-shield, Courtland, Kansas
The KBA awarded $40,000 to Nutri-Shield, a company engaged in development, manufacturing, marketing, and sales of preservatives. The company’s primary business is the removal of odors and flavors from commercial grade preservatives used in food and health care and cosmetic products. Funding is for assistance in developing and transitioning a process for synthesizing sorbic acid from the carbohydrate fraction of corn from proven lab scale to a plant setting. Funds will be split between research vouchers and equipment and lab needs (7/13/06).
Expected or Realized Outcomes: Approximately $85,238 in capital expenditures and $35,000 in research funding.
MGP Ingredients, Atchison, Kansas
The KBA awarded $40,000 for research vouchers to K-State for creating higher value products from distillers dried grains, millfeeds, corn stalks and wheat straw that segregate into several fractions and are used in subsequent biorefinery operations and products. MGPI is a recognized pioneer in the development and commercialization of bio-based products as well as specialty starches and proteins for use in a wide array of consumer goods. It is embarking on an aggressive plan to develop a substantial business based on bio-based, biodegradable resins designed to economically replace plastic resin (7/13/06).
Expected or Realized Outcomes: Approximately six new employees.
Sunflower Integrated Bioenergy Center, Holcomb, Kansas
The KBA awarded $13,000 for a Phase I project to the National Institute for Strategic Technology Acquisition and Commercialization (NISTAC) to identify and commercialize renewable energy technology for western Kansas. Funding will be matched by Sunflower Electric Power Corporation and NISTAC (7/13/06).
Expected or Realized Outcomes: Attracted matching funds for a study leading to the creation of an integrated bioenergy center.
IdentiGEN North America, Lawrence, Kansas
The KBA awarded $125,000 to IdentiGEN for a research voucher for a K-State professor and financial assistance to defray the cost of scientific equipment in Kansas laboratories. IdentiGEN is an innovative provider of DNA-based solutions to the agri-food industry with plans to locate headquarters for its U.S. operations in Lawrence (4/11/06).
Expected or Realized Outcomes: Approximately 35 new employees, $41,500 in research funding, and $1.9 million in capital expenditures.
Expansion and Attraction
ANOxA CORP
The KBA awarded $300,000 to ANOxA CORP, an animal-health biotechnology company, for the commercialization of a new drug to treat a common equine disorder should it move its headquarters to Kansas. The company is expected to hire seven employees upon relocation (10/28/08).
Expected or Realized Outcomes: Seven new employees, relocation to Kansas, and $6 million in equity financing.
MGP Ingredients, Atchison, Kansas
The KBA awarded $500,000 for the development and further commercialization of biobased, biodegradable resins to economically replace plastic. The biobased resin can be used for products such as disposable cutlery, DVD cases, and bottle caps — and is biodegradable (7/15/08).
Expected or Realized Outcomes: 54 new jobs and $9.9 million in capital investment.
Ventria Bioscience, Junction City, Kansas
The KBA awarded a $3.75 million convertible note as part of a $7.5 million financing plan to expand operations, including an increase in employment and expanded production capacity in Kansas. The financing will help the company prepare for the commercial launch of its pediatric health product, which was clinically shown to shorten the duration of acute childhood diarrhea, the second leading killer of children under the age of 5, claiming 2 million lives annually on a global basis. The company’s patented protein expression technology, ExpressTec, is highly efficient and uses rice as a biological factory to produce protein-based products for human health and nutrition (6/5/08).
Expected or Realized Outcomes: $3.75 million in private investment and 19 full-time jobs and seven part-time jobs.
Vince and Associates Clinical Research, Overland Park, Kansas
The KBA awarded $200,000 to expand the company’s pharmaceutical clinical research trials capacity to meet significant increases in the demand for clinical studies. The expansion doubles floor space with a dedicated 50-bed clinical research facility for Phase I trials (6/5/08).
Expected or Realized Outcomes: More than $1 million in private capital investment and 38 full- and part-time employees over the next three years.
Thermo Fisher Scientific / Remel, Lenexa, Kansas
The KBA awarded $1.25 million to Thermo Fisher Scientific for the expansion of its Lenexa operations, which manufactures and distributes Remel products. The company is a global manufacturer of a wide range of high-quality microbiology products used in clinical, industrial, research, and academic laboratories (9/28/07).
Expected or Realized Outcomes: 90 to 180 new employees and $7 to $12 million in capital expenditures.
City of Emporia, Kansas / Renewable Energy Group
The KBA awarded $300,000 over 10 years to the City of Emporia to support the attraction of Renewable Energy Group, the nation’s leader in biodiesel marketing, which plans to build a commercial-scale, multiple feedstock biodiesel production facility in Emporia. When the facility opens, Renewable Energy Group’s biodiesel network is slated to market more than 310 million gallons of biodiesel a year (7/10/07).
Expected or Realized Outcomes: Approximately 30 new employees and $65 million in capital expenditures.
Fort Dodge Animal Health, Overland Park, Kansas
The KBA awarded $3.5 million and 30 acres of land in the Kansas Bioscience Park to Fort Dodge Animal Health for the expansion of its North American research and development laboratories in Olathe, Kansas (7/10/07).
Expected or Realized Outcomes: 215 new employees and approximately $39 million in capital expenditures.
Edenspace Systems Corporation, Junction City, Kansas
The KBA awarded $200,000 to Edenspace Systems, which seeks to become a key supplier in the renewable fuels industry by engineering crops to lower the cost of cellulosic ethanol. The company has been awarded more than $2.8 million in development funding from the U.S. Department of Energy and has signed key development agreements with the U.S. National Renewable Energy Laboratory (NREL), USDA and the leading ethanol facility development company, ICM, Inc. (3/13/07).
Expected or Realized Outcomes: Approximately 30 new employees, $2.8 million in federal research funding, and $5 million in investment capital.
Hospira, McPherson, Kansas
The KBA awarded $64,000 Hospira, a global specialty pharmaceutical and medication delivery company with 14 manufacturing facilities worldwide, including a facility in McPherson. A $60 million expansion of the McPherson plant has been completed, and funding supports an effort to encourage qualified students to investigate careers in the biosciences and to recruit, hire, and retain recently graduated scientists from Kansas universities (1/9/07).
Expected or Realized Outcomes: Approximately 8 new employees.
OncImmune, Lenexa, Kansas
The KBA awarded $2.5 million to OncImmune, which was founded in 2003 to commercialize technology developed in the laboratories of Professor John Robertson, a professor of surgery at Nottingham University. The focus of Oncimmune’s technology is on the early detection of cancer, in particular breast cancer, and the company plans to collaborate with the University of Kansas on pharmaceutical chemistry at the Lawrence campus and on cancer clinical research at the KU Medical Center. The company is establishing its North American headquarters in Kansas (10/12/06).
Expected or Realized Outcomes: Approximately 480 new employees and $2.1 million in research funding.
Junction City, Kansas / Ventria Bioscience
The KBA awarded $1 million to Junction City to support the attraction of Ventria Bioscience, a plant-made pharmaceutical and plant-made industrial products company expanding its nursery, greenhouse, field production and bioprocessing operations to Junction City. The company plans to grow genetically modified rice which can be processed into pharmaceutical, medical food ingredients and bioprocessing ingredients (10/12/06).
Expected or Realized Outcomes: Approximately 95 new employees and $4.5 million in capital expenditures.
American Ingredients Company / Caravan Ingredients, Lenexa, Kansas
The KBA awarded $1 million to this leading researcher and manufacturer of functional bakery ingredients and health products with plans to relocate its national headquarters to Lenexa. Funding will be equally divided between Kansas research universities in the form of research vouchers and the company for purchasing and sustaining research equipment (7/13/06).
Expected or Realized Outcomes: Approximately 100 new employees and $500,000 in research funding.
Topeka Chamber of Commerce, Topeka, Kansas
The KBA awarded $13,388 to the Topeka Chamber of Commerce for due diligence to facilitate the attraction process of a bioscience company seeking to expand its production and bioprocessing operations (7/13/06).
Expected or Realized Outcomes: A due diligence report.
Quintiles, Overland Park, Kansas
The KBA awarded $3.5 million to defray moving and employment training costs associated with the company’s relocation of its clinical development services, clinical pharmacology, and Phase I clinical research units to Overland Park (4/11/06).
Expected or Realized Outcomes: Approximately 650 new employees and $45 million in capital expenditures.
Hospira, McPherson, Kansas
The KBA awarded $200,000 to Hospira, a global specialty pharmaceutical and medication delivery company with 14 manufacturing facilities worldwide, including a facility in McPherson. A $60 million expansion of the McPherson plant has been completed, and funding supports an effort to encourage qualified students to investigate careers in the biosciences and to recruit, hire, and retain recently graduated scientists from Kansas universities (4/11/06).
Expected or Realized Outcomes: Approximately 33 new employees.
JACAM Chemicals, Sterling, Kansas
The KBA awarded $500,000 to JACAM Chemicals, which provides services and products to numerous industries including oil, gas, pipeline, and municipal and industrial water systems. Funding is for the purchase of scientific equipment and recruitment of research personnel for an expanded facility in Rice County (4/11/06).
Expected or Realized Outcomes: Approximately 60 new employees and $4.98 million in capital expenditures.
Infrastructure
BioMedical Entrepreneurial Research Incubator Renovation Project, Kansas City, Kansas
The KBA awarded $2 million to partially match a $3 million grant awarded by the federal government to create new wet-lab incubator space at KU Medical Center’s Breidenthal Research Building. The addition will help area start-up companies grow and stay in Kansas as they develop new drugs and medical devices that will not only help improve human health but expand the state’s economy (4/8/08).
Expected or Realized Outcomes: $4 million in additional capital investment and a projected 136 new jobs and 26 companies, with 16 of the companies graduating from the incubator into other space, generating $40 million in revenue plus $10 million annually going forward.
Kansas Bioscience Park, Olathe, Kansas
The KBA awarded $7.6 million for the development of a 105-acre bioscience park in Olathe that will be home to the K-State Olathe Innovation Campus and growing bioscience companies. Funding is for work such as landscaping, utility installation, engineering, street construction, surveys, excavation, grading, sidewalks, streetlights, and site preparation (1/9/07).
Expected or Realized Outcomes: Approximately $7.6 million in capital expenditures and approximately 1,800 new employees.
City of Manhattan, Kansas / National Institute for Strategic Technology Acquisition and Commercialization
The KBA awarded $1 million to Manhattan for construction of and equipment for wet lab incubator space (7/13/06).
Expected or Realized Outcomes: Up to 200 new employees and approximately $5.65 million in capital expenditures.
Wet Lab Upgrade KU Medical Center, Kansas City, Kansas
The KBA awarded $100,000 to KU Medical Center to upgrade the wet lab at the Kansas City Biotechnology Development Center at the KUMC Research Institute (7/13/06 and 1/9/07)
Expected or Realized Outcomes: Approximately $100,000 in capital expenditures.
Wet Lab Planning and Architecture, Olathe, Kansas
The KBA awarded $150,000 for planning and architectural work for the Kansas Bioscience Park and K-State Olathe Innovation Campus (7/13/06).
Expected or Realized Outcomes: Architecture design.
Other
Biosecurity Research Institute Training and Education Enhancement, Manhattan, Kansas
The KBA awarded $1,548,000 to implement technologies at the Biosecurity Research Institute (BRI) at Kansas State University and enhance the ability to offer distance educational programming via satellite or over the Internet. The BRI’s integrated training suite (ITS) is a combined modern classroom and fully functional laboratory with all the equipment common to a biosafety level 3 research laboratory. With additional technologies, the ITS will become a functioning educational studio permitting the BRI learning experience to include the production of professional-level DVDs of training programs. The BRI training and education DVDs will be offered for national and international distribution, further demonstrating leadership in this arena and greatly extending the impact of K-State. This leadership in biosecurity education and training will serve as a national resource for training the staff that will occupy the proposed National Bio and Agro-Defense Facility (2/26/08).
Expected or Realized Outcomes: Enhance the BRI as an attractor for the NBAF, for new bio-businesses, and additional research programs for the BRI. At just 27 percent occupancy, the ITS could generate $564,300 per year in revenue, and, with training and education programs in the lecture hall at a 57 percent occupancy rate, there is a potential to generate $945,000 per year in funding.
Kansas Bioscience Fund
Funding will support the creation of a fund to increase the amount of private investment capital available in Kansas for Kansas bioscience companies in the seed or early stage investment capital (5/25/07).
National Bio and Agro-Defense Facility, Manhattan, Kansas
The Department of Homeland Security is seeking a location to build a $451 million federal laboratory to research and develop countermeasures to animal, human, and zoonotic diseases. Kansas is in the group of five finalists for the facility, and KBA funding supports the effort to bring the NBAF to Kansas (1/9/07 and 9/28/07).
Expected or Realized Outcomes: 300 new employees and $451 million in capital expenditures.
Kansas City Area Development Council
Assistance supported the development of a business recruitment marketing plan by the KC metropolitan area’s umbrella economic development organization to enhance marketing efforts aimed at attracting life science companies (7/13/06).
Kansas City Area Life Sciences Institute
Assistance provided matching funds to support a federal planning grant for a regional wet lab incubator to be located at KU Medical Center. The Kansas City Area Life Sciences Institute and the National Institute for Strategic Technology Acquisition and Commercialization also provided matching funds (7/13/06).
KansasBIO
Assistance supports Kansas’ outreach and attraction activities at the annual BIO International Convention, the preeminent gathering of tens of thousands of bioscientists and business and a key Kansas marketing opportunity (1/5/06, 10/12/06, and 9/28/07).
Heartland BioVentures
Funding supports a KBA program emphasizing business formation and acceleration to grow bioscience companies and help them raise venture capital investment (1/5/06 and 5/25/07).